Both Tirzepatide and Semaglutide have similar safety rules
Tesofensine is currently in clinical development for the treatment of obesity, however, the pharmacological basis for its strong effect in obesity management is not clarified
It is feeling strong, confident, and truly comfortable in the skin you are in.Call (952) 479-0915 | Text (952) 479-0603 | Book a consultation online with us!
However, long-term use can lead to significant side effects, including: Disrupted gut health
[1] [3] Preparation (before injection): Remove the Wegovy pen from the refrigerator 3060 minutes before use to allow it to reach room temperature, which reduces injection discomfort

Sources Healthline: Weight Loss is Often a Losing Battle NIH: Glucagon-like peptide 1 (GLP-1) Cleveland Clinic: GLP-1 Agonists NIH: Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes American Diabetes Association: GLP-1 Receptor in Pancreatic -Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner NIH: GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca2+ channels NIH: Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function FDA: Concern Over Compounded GLP-1 Drugs FDA Label: OZEMPIC (Semaglutide Injection) Medication Guide FDA Label: WEGOVY (Semaglutide Injection) Medication Guide FDA Label: RYBELSUS (Oral Semaglutide) Medication Guide FDA Label: MOUNJARO (Tirzepatide Injection) Medication Guide FDA Label: ZEPBOUND (Tirzepatide Injection) Medication Guide Important Medical Information and Disclaimers Medical Disclaimer This information is for educational use only